KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Receivables (2016 - 2025)

Historic Receivables for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $14.3 billion.

  • Pfizer's Receivables fell 132.17% to $14.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $14.3 billion, marking a year-over-year decrease of 132.17%. This contributed to the annual value of $11.5 billion for FY2024, which is 89.05% down from last year.
  • Latest data reveals that Pfizer reported Receivables of $14.3 billion as of Q3 2025, which was down 132.17% from $12.1 billion recorded in Q2 2025.
  • Pfizer's Receivables' 5-year high stood at $16.2 billion during Q4 2022, with a 5-year trough of $10.2 billion in Q3 2023.
  • Moreover, its 5-year median value for Receivables was $11.6 billion (2023), whereas its average is $12.3 billion.
  • Its Receivables has fluctuated over the past 5 years, first surged by 3997.82% in 2022, then tumbled by 3368.12% in 2023.
  • Pfizer's Receivables (Quarter) stood at $11.5 billion in 2021, then dropped by 5.03% to $11.0 billion in 2022, then rose by 5.61% to $11.6 billion in 2023, then dropped by 0.89% to $11.5 billion in 2024, then increased by 24.4% to $14.3 billion in 2025.
  • Its last three reported values are $14.3 billion in Q3 2025, $12.1 billion for Q2 2025, and $11.8 billion during Q1 2025.